Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2022 13:58 ET | Source: Cabaletta Bio

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
August 11, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
May 18, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
May 17, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference

PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
May 12, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 – – Multiple...
May 02, 2022 16:30 ET | Source: Cabaletta Bio

Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
April 06, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
March 17, 2022 07:00 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4 and 28-day safety data for cohort A5 expected at upcoming scientific...
March 01, 2022 08:00 ET | Source: Cabaletta Bio

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

– Fast Track Designation granted to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis – PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE)...
February 28, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...